Get the Stockscreener App
14.49
1.02%
-0.15
Dbv Technologies Adr stock is traded at $14.49, with a volume of 9,802.
It is down -1.02% in the last 24 hours and up +12.33% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$14.64
Open:
$14.36
24h Volume:
9,802
Relative Volume:
0.11
Market Cap:
$396.95M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-13.80
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
-9.38%
1M Performance:
+12.33%
6M Performance:
+61.90%
1Y Performance:
+280.71%
1-Day Range:
$14.36
$14.58
1-Week Range:
$13.88
$16.39
52-Week Range:
$2.2045
$18.00
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
14.49 | 494.70M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.77 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.76 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.92 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
829.03 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.21 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Appoints Dr. Philina Lee to Board - TipRanks
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
Health Care And Telecom Drive European ADR Gains In The US - Finimize
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
DBV Technologies Reports Third Quarter 2025 Financial Results - TradingView
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Healthcare And Biotech Led European ADRs As Markets Steadied - Finimize
Optimistic Outlook for DBV Technologies Amid Promising Viaskin Peanut Advancements - TipRanks
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Orion, Nio, Alibaba Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Pre-market Movers: GNPX, BFRI, DBVT See Big Swings - RTTNews
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages - Defense World
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving PremarketAehr Test System (NASDAQ:AEHR), Amkor Tech (NASDAQ:AMKR) - Benzinga
DBV Technologies raises $30 million through ADS sale on Nasdaq - Investing.com
$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
DBV Technologies Announces Board Member Resignation - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
European ADRs In The US See Modest Gains On Health And Tech - Finimize
What drives DBV Technologies SA DBV stock priceLarge Cap Stability Picks & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Can DBV Technologies S.A. Depositary Receipt stock reach $100 price target2025 Market Trends & Expert Curated Trade Ideas - newser.com
DBV Technologies Announces Resignation of Board Member - GlobeNewswire
Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
DBV Technologies stock rating reiterated at Market Outperform by JMP - Investing.com
Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75 - Defense World
Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) Price Target at $14.75 - Defense World
DBV Technologies Establishes an At-The-Market Program on Nasdaq - MarketScreener
DBV Technologies Launches $150M ATM Equity Offering - The Globe and Mail
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
0.09%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):